Skip to main content

Table 3 Univariate and multivariate analysis of predictive factors for pCR in LARC patients (n = 901)

From: Worse treatment response to neoadjuvant chemoradiotherapy in young patients with locally advanced rectal cancer

Variables Univariate analysis Multivariate analysis
HR 95% CI p value HR 95% CI p value
Sex (male vs. female) 1.351 0.973–1.875 0.073    
Age (≥40 years vs. < 40 years) 2.087 1.020–4.269 0.044 2.382 1.105–5.137 0.027
ASA 0.964 0.686–1.353 0.831    
Distance from the anal verge 0.919 0.856–0.986 0.018 0.949 0.878–1.025 0.181
Tumor size
  ≤ 1.8 cm Reference Reference < 0.001 Reference Reference < 0.001
 1.9–3.1 cm 6.764 4.019–11.385 < 0.001 5.806 3.412–9.878 < 0.001
  ≥ 3.2 cm 2.022 1.212–3.373 0.007 1.853 1.101–3.119 0.020
Time interval between NCRT and surgery 1.041 0.988–1.097 0.131    
Pre-NCRT cT stage 0.731 0.553–0.967 0.031 0.816 0.607–1.097 0.177
Pre-NCRT cN stage 0.550 0.338–0.895 0.016 0.560 0.332–0.943 0.029
Post-NCRT CEA level 0.381 0.224–0.647 < 0.001 0.873 0.805–0.946 0.001
Post-NCRT CA19–9 level 0.492 0.219–1.101 0.084    
Chemotherapy regimen 1.083 0.783–1.499 0.630    
Radication dose reduction 0.978 0.360–2.653 0.965    
NCRT complications 0.900 0.641–1.264 0.542    
  1. pCR Pathological complete response; NCRT Neoadjuvant chemoradiotherapy; HR Hazard ratio; CI Confidential interval; ASA American Society of Anesthesiologists; CEA Carcinoembryonic Antigen; CA19–9 Carbohydrate Antigen 19–9